Bill
S 3267
Bill S 3267 expands Medicare to cover blood-based dementia screening tests, enabling earlier diagnosis and treatment for seniors, improving health outcomes and reducing costs.
Title: A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of blood-based dementia screening tests.
Bill Number: S 3267
Introduced: November 20, 2025
Status: Introduced in Senate
Classification: Bill
The primary purpose of Bill S 3267 is to enhance Medicare coverage by including blood-based dementia screening tests. This legislation aims to improve early detection and diagnosis of dementia, which can lead to better management of the condition and improved outcomes for patients.
Medicare Coverage Expansion: The bill proposes to amend Title XVIII of the Social Security Act to specifically include coverage for blood-based tests that screen for dementia.
Screening Tests: The legislation focuses on tests that can identify biomarkers associated with dementia, potentially allowing for earlier intervention and treatment.
Implementation Timeline: While specific implementation dates are not detailed in the bill, the introduction indicates a commitment to expediting the process of integrating these tests into Medicare coverage.
Medicare Beneficiaries: Seniors and individuals eligible for Medicare who may be at risk for dementia would benefit from access to these screening tests, facilitating earlier diagnosis and treatment options.
Healthcare Providers: Physicians and healthcare facilities that provide dementia care would need to adapt to the inclusion of these tests in their diagnostic protocols.
Researchers and Developers: Companies and organizations involved in the development of blood-based dementia screening tests may see increased demand and funding opportunities as a result of this legislation.
Healthcare Costs: Early detection of dementia through screening could potentially reduce long-term healthcare costs associated with advanced dementia care by allowing for timely interventions.
Public Health: Improved screening could lead to better public health outcomes by increasing awareness and understanding of dementia, ultimately benefiting society as a whole.
Bill S 3267 represents a significant step towards improving dementia care for Medicare beneficiaries by providing coverage for innovative blood-based screening tests. If enacted, this legislation could enhance early diagnosis and treatment, ultimately benefiting patients and the healthcare system.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
